Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Delays In Approving Clinical Trials, Poor IP Protections Block Access To Innovative Drugs - EU Chamber Of Commerce

This article was originally published in The Pink Sheet Daily

Executive Summary

Excellent clinical trial centers and a good medical infrastructure make China well-qualified to better integrate global clinical trials, increase cooperation with world-class clinicians and speed up the regulatory process, according to an EU Chamber position paper.

You may also be interested in...



Protectionist Economic Policies Create Roadblocks For Foreign Companies In China, Says U.S. Treasury Secretary

BEIJING - As the U.S. Senate held hearings on the Chinese exchange rate and overall economic policies that are said to be underlying an immense trade imbalance and blocking American businesses from competing freely in China, Treasury Secretary Timothy Geithner outlined an array of new and potential countermeasures

European Union Chamber Calls For Market Opening, Equal Access In China; €1 Trillion In WTO Procurement At Stake

BEIJING - Nearly a decade after joining the World Trade Organization, which requires all members to provide unfettered access to national markets and equal treatment to foreign and domestic business competitors, China is falling short across many areas, according to the leaders of the European Union Chamber of Commerce in China

Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers

BEIJING - Unless China does more to crack down on counterfeiting and contamination in its pharmaceutical industry, the United States could see a repeat of Chinese-made drugs or raw components causing severe adverse reactions in American hospitals, according to a Washington, D.C.-based scholar

Related Content

Topics

UsernamePublicRestriction

Register

PS071325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel